Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 03, 2025
CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma.
Journal: The New England journal of medicine
Published: February 12, 2025
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.
Journal: The New England journal of medicine
Published: January 08, 2025
Measurement of the Isolated Nuclear Two-Photon Decay in ^{72}Ge.
Journal: Physical review letters
Published: December 18, 2023
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 17, 2023
Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study.
Journal: Seminars in oncology nursing
Published: October 06, 2023
Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation.
Journal: Blood advances
Published: September 11, 2023
Teclistamab: Mechanism of action, clinical, and translational science.
Journal: Clinical and translational science
Published: August 18, 2023
Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Journal: Targeted oncology
Published: August 08, 2023
Last Updated: 09/26/2026